Home Mobile games Living community 5G technology Commercial street Fashion icon More

Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials

KYOTO,Japan,April 15,2025 -- Rege Nephro Co.,Ltd. (Headquarter: Kyoto,Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals,Inc. (Headquarters: Boston,MA; NASDAQ:SYRS),through a mutual agreement. The acquisition was completed on February 26,2025.

Tamibarotene (RN-014) is a retinoic acid receptor agonist for which Rege Nephro is currently conducting a Phase 2 clinical trial in Japan in autosomal dominant polycystic kidney disease (ADPKD). Rege Nephro expects to initiate clinical trials in the United States,after confirming the efficacy and safety in Japan. Syros Pharmaceuticals has previously carried out a Phase 3 clinical trial of Tamibarotene for indications including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

This acquisition,encompassing their clinical and non-clinical data including human safety study for New Drug Application (NDA),contracts with a contract manufacturing organization (CMO),and Tamibarotene active pharmaceutical ingredient (API) and drug products,is expected to enhance Rege Nephro's capabilities and streamline operations for its clinical trial operations in the United States.

About Rege Nephro:


Rege Nephro,founded in 2019,is a clinical-stage biotech company leveraging technology based on research of Prof. Kenji Osafune,deputy director of the Center for iPS Cell Research and Application (CiRA),Kyoto University. The company is developing therapeutics and cell therapy for diseases related to the kidneys,liver,and pancreas. For more information,please visit www.regenephro.co.jp/en.

About RN-014:


RN-014 is a therapeutic candidate for autosomal dominant polycystic kidney disease (ADPKD). It is a retinoic acid receptor (RAR) agonist expected to suppress cyst formation and improve renal function. Rege Nephro initiated a Phase 2 clinical trial in December 2023,and enrollment for the second stage has now been completed. To date,no significant safety concerns have arisen and preliminary efficacy has been demonstrated.

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.

Newest

lost diver found alive 100 miles and a continent away

madeleine mccann suspect to walk free in weeks as evidence not 'strong enough'

british man dies in benidorm after drowning in late evening swim

saudi arabia's 'ski resort in the desert' in race against time for winter games

british gran locked in cell for 22 hours after losing passport on flight

families of two british mums run over in ibiza give major update

©Copyright 2009-2020 Startup Weekly    Contact Us  SiteMap